A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients
Cidofovir could be an effective drug for the treatment of Anal Intraepithelial Neoplasia(AIN).
HIV
DRUG: Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
Percentage of patients with complete regression of anal intraepithelial neoplasia, Describe the percentage of patients achieving complete regression of anal intraepithelial neoplasia (AIN), as confirmed by means of high-resolution anoscopy and biopsy, 8 Weeks
Describe the percentage of patients that reduce the degree of Anal dysplasia, Describe the percentage of patients that reduce the degree of Anal dysplasia, 8 weeks|Describe the percentage of patients that reduces the extent Intraepithelial Anal Dysplasia quadrants, although not complete regression, Describe the percentage of patients that reduces the extent Intraepithelial Anal Dysplasia quadrants, although not complete regression, 8 Weeks|Time to relapse, Describe the percentage of patients with recurrence after complete regression of HSIL and median time to relapse, 8 Weeks|Percentage of patients with clear of Human papillomavirus, Describe the percentage of patients in whom Human Papillomavirus clears after treatment with cidofovir, 8 Weeks|Percentage of adverse events, Describe the number of patients with adverse events as a measure of safety and tolerability, 8 weeks|Treatment effect, Prospective Clinical Trial exploratory nature of the effect of treatment., 8 Weeks
Cidofovir could be an effective drug for the treatment of Anal Intraepithelial Neoplasia(AIN).